HK1135618A1 - Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives - Google Patents

Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Info

Publication number
HK1135618A1
HK1135618A1 HK10103311.4A HK10103311A HK1135618A1 HK 1135618 A1 HK1135618 A1 HK 1135618A1 HK 10103311 A HK10103311 A HK 10103311A HK 1135618 A1 HK1135618 A1 HK 1135618A1
Authority
HK
Hong Kong
Prior art keywords
methotrexate
toxicity
compositions
given
methods
Prior art date
Application number
HK10103311.4A
Other languages
English (en)
Inventor
Rashida A Karmali
Original Assignee
Savvipharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savvipharm Inc filed Critical Savvipharm Inc
Publication of HK1135618A1 publication Critical patent/HK1135618A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
HK10103311.4A 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives HK1135618A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/655,801 US7601834B2 (en) 2005-02-22 2007-01-18 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
PCT/US2008/000754 WO2008088909A1 (en) 2007-01-18 2008-01-18 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Publications (1)

Publication Number Publication Date
HK1135618A1 true HK1135618A1 (en) 2010-06-11

Family

ID=39637680

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13105058.3A HK1178148A1 (en) 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
HK10103311.4A HK1135618A1 (en) 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13105058.3A HK1178148A1 (en) 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Country Status (10)

Country Link
US (1) US7601834B2 (es)
EP (1) EP2104502B1 (es)
JP (2) JP5916040B2 (es)
KR (1) KR20090111311A (es)
CN (2) CN102924456B (es)
AU (1) AU2008206575B2 (es)
CA (1) CA2675246C (es)
HK (2) HK1178148A1 (es)
IL (1) IL199902A (es)
WO (1) WO2008088909A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415388B2 (en) * 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
KR20110031947A (ko) * 2008-07-07 2011-03-29 주식회사 머젠스 오로틱산, 그의 염 또는 유도체를 포함하는 히아루론산 또는 글리코사미노글리칸의 생합성 촉진용 조성물
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
CN108553420A (zh) * 2017-11-20 2018-09-21 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
CN112969462B (zh) * 2018-11-12 2024-03-19 株式会社力森诺科 乳清酸衍生物的制造方法
CN112094322B (zh) * 2019-06-18 2022-04-22 首都医科大学 His-Gly-Lys修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210865B (de) * 1962-03-05 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung des 2, 6-dioxo-tetrahydropyrimidin-4-carbonsauren Salzes des 4-Amino-5-imidazolcarbonsaeureamids
CA2128205C (en) 1992-01-27 2004-03-30 Hiroharu Matsuoka Methotrexate derivatives
US5958928A (en) 1995-03-27 1999-09-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agents containing methotrexate derivative
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
JP4422796B2 (ja) * 1995-07-21 2010-02-24 タクティカル セラピューティクス インコーポレイテッド アミノイミダゾールカルボキサミドおよび５−アミノ、または置換アミノ１，２，３−トリアゾールの塩による癌の治療および阻止
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
JP5559535B2 (ja) * 2007-08-06 2014-07-23 サヴィファーム インコーポレイテッド 薬剤をオロチン酸誘導体として投与することで薬剤の組織内濃度を下げる組成物及びその方法

Also Published As

Publication number Publication date
JP5916040B2 (ja) 2016-05-11
HK1178148A1 (en) 2013-09-06
KR20090111311A (ko) 2009-10-26
JP2014196324A (ja) 2014-10-16
JP2010516683A (ja) 2010-05-20
EP2104502A1 (en) 2009-09-30
EP2104502B1 (en) 2015-05-06
IL199902A (en) 2017-07-31
US20070179145A1 (en) 2007-08-02
JP6057947B2 (ja) 2017-01-11
AU2008206575B2 (en) 2013-02-21
IL199902A0 (en) 2010-04-15
CN101583362A (zh) 2009-11-18
CA2675246C (en) 2014-09-23
WO2008088909A1 (en) 2008-07-24
EP2104502A4 (en) 2011-08-10
CA2675246A1 (en) 2008-07-24
US7601834B2 (en) 2009-10-13
CN101583362B (zh) 2013-04-17
AU2008206575A1 (en) 2008-07-24
CN102924456B (zh) 2015-03-25
CN102924456A (zh) 2013-02-13

Similar Documents

Publication Publication Date Title
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
PT2050749T (pt) Derivado de pirimidina como inibidador de pi3k e sua utilização
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
TWI347321B (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
IL202622A (en) Purin derivatives and pharmaceuticals containing them
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
IL198675A0 (en) Novel aminopyrimidine derivatives as plk1 inhibitors
HK1123296A1 (en) Pyrazine derivatives and use as pi3k inhibitors
HK1135618A1 (en) Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
EP2001338A4 (en) FURNITURE
EP2024272A4 (en) AMID DERIVATIVES AS ION CHANNEL NIGANDS, AND PHARMACEUTICAL COMPOSITIONS AND USER METHOD THEREFOR
LT1917218T (lt) Iš dalies deacetilinto chitino darinių kompozicijos
ZA201001107B (en) Citrus oil compositions and methods of use
IL200576A0 (en) Inhibitors of rtp801 and their uses
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
HK1210948A1 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
SG10201510301UA (en) Compositions incorporating sesamin-class compounds and vitamin b1 class compounds
ZA200808190B (en) Malonamide derivatives as gamma secretase inhibitors
ZA200900416B (en) Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
PT2043661E (pt) Uso de tilvalosina como agente antiviral
EP2076281A4 (en) STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF
IL186606A0 (en) Compositions and uses of amooranin compounds
IL193346A0 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
ZA200903127B (en) Novel aminopyrimidine derivatives as PLK1 inhibitors